MeSH tree: C04.557.386.480.150
An international team of doctors led by Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai, has made a major breakthrough in treating a common and challenging form ...
Jan 23, 2025
0
0
A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing certain receptors from their surfaces and blocking cancer gene activity, according to a preclinical ...
Jan 15, 2025
0
37
A new type of cell-based immunotherapy shows promise for B-cell lymphomas, and due to innovations in manufacturing, could make future cellular immunotherapies less expensive and more accessible to patients.
Jan 14, 2025
0
23
An investigational therapy is demonstrating preclinical promise against non-Hodgkin lymphoma by boosting natural killer cells and efficiently annihilating the malignancy without toxicity to the patient, a team of cancer biologists ...
Scientists at EPFL have developed "lymphomoids," a pioneering cancer model that preserves the structure and multicellular composition of lymphoma tumors in the lab. Lymphomoids offer an innovative way to test the efficacy ...
Dec 18, 2024
0
13
A simple dietary supplement may provide a new approach to boost CAR T cell function, according to a study by researchers in the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine's Abramson Cancer ...
Dec 7, 2024
0
64
For many doctors and researchers, immunotherapy that uses someone's own immune system to target and attack cancer cells is the next and best frontier of cancer treatment. Chimeric antigen receptor T-cell therapy, or CAR-T ...
Sep 3, 2024
0
1
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity ...
Jul 24, 2024
0
0
A study led by researchers at Brighton and Sussex Medical School (BSMS) has unveiled an approach to predicting the effectiveness of treatments for patients with diffuse large B-cell lymphoma (DLBCL), a common form of blood ...
Jul 15, 2024
0
18
CAR-T cell therapy, which targets a specific protein on the surface of cancer cells, causes tumors to shrink or disappear in about half of patients with large B-cell lymphoma who haven't experienced improvement with chemotherapy ...
Jul 10, 2024
0
9
